Hemovigilance

Taleghani, Behrouz Mansouri; Heuft, Hans‐Gert

doi:10.1159/000363597

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that common hemovigilance (HV) strategies—intended to collect, assess, and address information on unexpected or undesirable effects of blood products [ 17 ]—rarely detect TTBI-related morbidity and mortality, particularly when passive surveillance is employed. Passive surveillance relies on accurate and timely reporting of suspected transfusion-associated adverse reactions (often by untrained personnel) and can lead to underreporting [ 11 , 18 ].…”

Section: Bacterial Contamination Of Plateletsmentioning

confidence: 99%

Bacterial contamination of platelets for transfusion: strategies for prevention

2018

View full text Add to dashboard Cite

Platelet transfusions carry greater risks of infection, sepsis, and death than any other blood product, owing primarily to bacterial contamination. Many patients may be at particular risk, including critically ill patients in the intensive care unit. This narrative review provides an overview of the problem and an update on strategies for the prevention, detection, and reduction/inactivation of bacterial contaminants in platelets. Bacterial contamination and septic transfusion reactions are major sources of morbidity and mortality. Between 1:1000 and 1:2500 platelet units are bacterially contaminated. The skin bacterial microflora is a primary source of contamination, and enteric contaminants are rare but may be clinically devastating, while platelet storage conditions can support bacterial growth. Donor selection, blood diversion, and hemovigilance are effective but have limitations. Biofilm-producing species can adhere to biological and non-biological surfaces and evade detection. Primary bacterial culture testing of apheresis platelets is in routine use in the US. Pathogen reduction/inactivation technologies compatible with platelets use ultraviolet light-based mechanisms to target nucleic acids of contaminating bacteria and other pathogens. These methods have demonstrated safety and efficacy and represent a proactive approach for inactivating contaminants before transfusion to prevent transfusion-transmitted infections. One system, which combines ultraviolet A and amotosalen for broad-spectrum pathogen inactivation, is approved in both the US and Europe. Current US Food and Drug Administration recommendations advocate enhanced bacterial testing or pathogen reduction/inactivation strategies (or both) to further improve platelet safety. Risks of bacterial contamination of platelets and transfusion-transmitted infections have been significantly mitigated, but not eliminated, by improvements in prevention and detection strategies. Regulatory-approved technologies for pathogen reduction/inactivation have further enhanced the safety of platelet transfusions. Ongoing development of these technologies holds great promise.

show abstract

Section: Bacterial Contamination Of Plateletsmentioning

confidence: 99%

Bacterial contamination of platelets for transfusion: strategies for prevention

2018

View full text Add to dashboard Cite

show abstract

“…Haemovigilance has become an integral part of blood safety worldwide as well as an essential component of quality management in a blood system and is needed for the continual enhancement of quality and safety of blood products and transfusion process using the lessons learned and associated with the use of blood products to take action to avoid that problem going wrong again. Haemovigilance may be interpreted as the ‘check’ step of the PDCA cycle (plan‐do‐check‐act or plan‐do‐check‐adjust), which is an iterative four‐step management method used for the control and continuous improvement of processes and products , so a well‐functioning haemovigilance system could be used as quality indicator for monitoring the blood transfusion safety, and also contribute significantly to evidence‐based transfusion medicine , and the resulting modifications to transfusion policies, standards and guidelines, as well as improvements to processes in blood services and transfusion practices in hospitals, lead to improved patient safety.…”

Section: Haemovigilance: the Best Quality Management System Of The Trmentioning

confidence: 99%

The haemovigilance: the best quality management system of the transfusion chain?

Liang

et al. 2018

ISBT Science Series

View full text Add to dashboard Cite

Background and Objectives Haemovigilance is an integral part of blood safety worldwide. Many haemovigilance systems are already in place or are developing, and national or regional haemovigilance systems have been implemented in several countries. In 2016, the WHO Global Database on Blood Safety reported that national haemovigilance system had been established in 70 countries, among which 38 countries were members of the International Haemovigilance Network by the end of August 2017. In this review, we retrospect the development and current status of haemovigilance to outline its function in transfusion chain. Materials and Methods Through contrasting the evolution of haemovigilance definition in different periods, by analysing its scope and breadth, and with the illustrating its achievements and challenges, we retrospect the development and current status of haemovigilance to outline its function in transfusion chain. Results Haemovigilance is becoming an important aspect of transfusion medicine,could be used as quality indicator for monitoring the blood transfusion safety, contribute significantly to evidence‐based transfusion medicine and results in improved policies, procedures and practices in the blood transfusion chain. Conclusions The scope of haemovigilance may cover the whole transfusion chain, from collection of blood and its components to follow‐up of recipients. Haemovigilance is an essential component of quality management in a blood system and haemovigilance is the best quality management system of the transfusion chain.

show abstract

“…In 2014 several papers considered the influence of blood product characteristics or modifications on product safety and transfusion efficacy [2][3][4][5][6]. The current issue deals with the nationwide implementation of pathogen inactivation (PI) for all platelet concentrates (PC) in Switzerland, as presented by Markus Jutzi and colleagues [7].…”

mentioning

confidence: 99%